Search
for
Sort by
Research
750-780 / 1000+ results
research Gleason grading controversies: what the chemoprevention trials have taught us
Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.
research Three Considerations Before Advising 5-α-Reductase Inhibitors for Chemoprevention
5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.
research Pertinence d’une chimioprévention à partir de l’étude PCPT
Finasteride shows promise for preventing prostate cancer, but more research is needed.
research Editorial Comment
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
research 410 NON-INVASIVE DIAGNOSIS OF PROSTATE CANCER FROM BODY FLUIDS USING A PANEL OF TUMOR SUPPRESSOR GENES
Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.
research Primary Cutaneous Rhabdoid Squamous Cell Carcinoma: A Case Report and Review of Molecular Features
Recognizing RSCC is crucial due to its aggressive nature and high risk of poor outcomes.
research 409 ANDROGEN RECEPTOR GENE POLYMORPHISM (SNP RS6152) – ITS RELATIONSHIP TO ANDROGEN-SENSITIVE GENES EXPRESSION IN BENIGN PROSTATIC HYPERPLASIA, CARCINOMA OF THE PROSTATE AND ANDROGENETIC ALOPECIA
Gene variation affects prostate issues and hair loss.
research 102 Methylation of CpG islands in promoter of type 2 5-α reductase and implications of finasteride resistance for BPH therapy
Methylation in specific gene region causes finasteride resistance in some BPH patients.
research Methylated CpG dinucleotides in 5-α reductase 2 gene might explain the finasteride-resistance in BPE patients
Methylated gene parts may cause finasteride-resistance in some enlarged prostate patients.
research Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?
Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.
research Stereotactic Body Radiation Therapy As a Derivative of Stereotactic Radiosurgery: Clinically Independent But With Enduring Common Themes
Stereotactic body radiation therapy and radiosurgery are advanced, precise treatments that target tumors while protecting healthy tissue.
research Study Answers Some Questions about Androgen Suppression Pre-Radiation, but Not All
Extending androgen suppression before radiotherapy offers no extra survival benefit for intermediate-risk prostate cancer.
research 5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence
5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
research The Role of 5αR Inhibitors in the Early Growth of Pca Cells
5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.
research PD02-05 SRD5A2 EXPRESSION IS A PREDICTOR OF RESPONSE TO FINASTERIDE IN THE MTOPS TRIAL
Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
research 5α‐Reductase Inhibitors
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
research PD23-01 INHIBITOR OF 5A-REDUCTASE TYPES II PROMOTES THE INFILTRATION OF CD8+T CELLS IN BPH TISSUES.
Finasteride increases CD8+ T cells in BPH tissues.
research Clinical research on preoperative application of finasteride in reducing transurethral resection syndrome
Preoperative finasteride can help prevent and reduce transurethral resection syndrome.
research MP73-14 TRANSURETHRAL RESECTION URINARY RETENTION PREDICTOR (TURP) SCORE: A NOVEL PERIOPERATIVE PREDICTOR OF POST-OPERATIVE URINARY RETENTION
A new score can help predict which patients might have trouble urinating after prostate surgery.
research 5-Alpha-Reductase Inhibitors and Combination Therapy
Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
research Triple Hormonal Blockade (ADT3): A Patient’s Perspective
Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
research Level-1 Data From the REDUCE Study and the PCPT Data
Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
research Saw palmetto and finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome
research Acute urinary retention: risks and management.
Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.
research 342 COMPARISON OF THE INCIDENCE OF SECONDARY CANCERS AFTER IMRT, BRACHYTHERAPY AND SURGERY FOR THE TREATMENT OF PROSTATE CANCER
Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.
research Финастерид в профилактике прогрессирования рака предстательной железы
Finasteride reduces prostate size, improves urination, and slows prostate cancer progression.
research Estudio clínico-patológico sobre el cáncer de próstata incidental en pacientes intervenidos bajo el supuesto diagnóstico de HBP sintomática
Incidental prostate cancer was found in 4.89% of patients undergoing surgery for benign prostatic hyperplasia.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
research Finasteride and prostate cancer
Finasteride's effects on prostate cancer are not clear from this text.